



EUSA Pharma (UK) Ltd Modern Slavery Act Statement 2020

Pursuant to Section 54 of the UK Modern Slavery Act 2015 (“Act”), EUSA Pharma (UK) Ltd and its subsidiaries (“EUSA”) are committed to preventing slavery and human trafficking in its business and supply chains. Over the past few years we have taken measures to establish anti-modern slavery practices in our business and supply chain. We continue to implement these measures as we are committed to our responsibilities under the Act. We provide the following statement to set out the steps taken by EUSA during the financial year ending 31st December 2020 to prevent modern slavery and human trafficking in our business and supply chains.

EUSA’s Structure

EUSA Pharma (UK) Ltd is based in the UK with subsidiary companies based in France, Germany, Spain, Italy, the Netherlands, Denmark, Switzerland, Australia, USA, Korea, and Brazil.

EUSA’s Business

EUSA is a rapidly growing global biopharmaceutical company which is committed to providing its oncology and rare disease focused products to patients across the world.

EUSA’s Supply Chains

Our supply chains include 1) the manufacture and supply of active pharmaceutical ingredients and excipients for pharmaceutical products; 2) the manufacture and packaging of finished pharmaceutical products; and 3) the promotion, sale and distribution of finished pharmaceutical products globally.

EUSA takes its responsibility seriously and regularly reviews its measures in its supply chain in relation to human rights, ethical conduct and personal data protection. EUSA requires all of its suppliers to subscribe to its Code of Conduct and ethics, and to formally agree to maintaining compliance with all applicable laws relating to safety, health, environment, competition and anti-trust, human rights, fair labour practices, unlawful discrimination and anti-bribery/anti-corruption.

Actions taken

EUSA has:

- Continued to ask anti-modern slavery compliance questions in our due diligence questionnaire used for new third parties we engage with.
- Implemented an Anti-Slavery and Human Trafficking Policy across the business which is mandatory for all employees and contractors to read and accept.
- Implemented mandatory annual training for its management and employees across the business through an e-learning platform.
- Updated our Code of Conduct to ensure we continue to conduct business with the highest standards of ethics.
- Implemented an ethics hotline to facilitate the reporting of any modern slavery concerns our employees or third parties may have.



- Updated our partner distribution contract templates to include clauses around anti-modern slavery and human trafficking in high-risk jurisdictions.
- Identified high risk suppliers (such as pre-wholesalers and manufactures) and have conducted further in-depth due diligence on such suppliers with a focus on anti-modern slavery and human trafficking.

This Statement has been approved by the Board of Directors and EUSA Pharma (UK) Ltd as of 7th December 2021.

A handwritten signature in blue ink, appearing to read "Carsten Thiel", written above a horizontal line.

Name: Dr. Frank Carsten Thiel

Title: CEO/Director

Date: 07/12/2021

A handwritten signature in blue ink, appearing to read "Emma Johnson", written above a horizontal line.

Name: Emma Johnson

Title: CFO/Director

Date: 07/12/2021

A handwritten signature in blue ink, appearing to read "Dev Kumar", written above a horizontal line.

Name: Dr. Dev Kumar MBBS BSc LL.B LL.M MA MRCOG PgCert

Title: General Counsel & Global Head of Compliance/Director

Date: 07/12/2021